Practices
Industries
Jurisdictions

Overview Of Changes in Information Security and Personal Data Protection Affecting Wholesale and Retail Trade of Medicinal Products

15 July 2025

Overview of changes in the sphere of information security and personal data (hereinafter referred to as the “PD”) that will affect the activities of organizations involved in the wholesale and retail trade of medicinal products. We remind you that starting from September 1, 2025, consents for PD processing must be stand-alone documents, separate from website Privacy Policies

Regulation Of Dietary Supplements Circulation in The Russian Federation: Overview of Changes Coming into Force on September 1, 2025

27 June 2025

On September 1, 2025, Federal Law No. 150-FZ dated June 7, 2025, 'On Amendments to Certain Legislative Acts of the Russian Federation' (hereinafter referred to as 'Federal Law No. 150'), will come into force, introducing a number of changes affecting the regulation of dietary supplements.


Guideline For Good Clinical Practice (Ich E6 R (3)): Overview of Key Changes in The New Edition

17 June 2025

On 23 July 2025, a part of the Good Clinical Practice Guideline, GCP E6 (R3), promulgated by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) comes into force. The development of new technologies, the rapidly evolving clinical trial (CT) ecosystem, and the need to respond quickly to deviations in CT processes have prompted the revision of the current version of GCP ICH E6(R2), which is valid until 22 July 2025.



Pausing FCPA: is anti-corruption compliance on pause?

24 February 2025

On 10 February 2025, President Trump signed an executive order, "Pausing Foreign Corrupt Practices Act Enforcement to Further American Economic and National Security" ("EO"): Is anti-corruption compliance on pause?

The EO establishes a moratorium on new investigations and enforcement actions under the FCPA for 180 days (with the possibility of a 180-day extension) and directs the Attorney General to review current investigations and enforcement actions within the specified timeframe, along with a revision of the guidelines governing FCPA investigations.